Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Embraces Total-Time Pre-Market Review Goals, With Shared Accountability

This article was originally published in The Gray Sheet

Executive Summary

FDA negotiators have warmed to the idea of total-time performance goals for the next round of medical device user fees, beginning in 2012, as long as FDA and industry share accountability for the time it takes to review new products.

You may also be interested in...

FDA Releases Guidance Documents On PMA, 510(k) Review Times And Goals

The agency outlined how it plans to calculate review times and meet performance goals for PMA and 510(k) submissions in two recent guidance documents.

Device Industry Expects Quicker Path To Market In Exchange For Doubling Of User Fees

The tentative agreement of $595 million in user fees over five years is more than companies had wanted to spend. But industry negotiators insist it is a good deal, tied to performance goals and process improvements they say will ensure greater speed and predictability in reaching the U.S. market.

Regulatory News In Brief

The latest on user fee negotiations and other device regulatory issues.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts